Medicamen Biotech Releases Quarterly Results; Board Approves Annual Report and Sets AGM Date
Medicamen Biotech Limited has announced the Unaudited Financial Results for the quarter ended June 30, 2026 (Standalone and Consolidated). The company's board meeting approved these results, along with the draft Annual Report and Cost Audit Report for the financial year 2025-26.The Board of Directors also determined that the 33rd Annual General Meeting will be held on Saturday, September 26, 2026, via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company set Saturday, September 19, 2026, as the cutoff date for determining shareholder eligibility for voting.
Financial Performance Highlights
The Unaudited Financial Results reflect various operational metrics across both standalone and consolidated segments. Key figures from Annexure-A include:| Metric | Q ended June 30, 2026 (Standalone) | Year Ended March 31, 2026 (Standalone) |
|---|---|---|
| Total Revenue | 4,471.43 | 18,195.01 |
| Total Expenses | 4,145.64 | 17,040.23 |
| Profit before Exceptional Items (before Tax) | 325.79 | 1,158.78 |
| Total Tax Expense | 73.10 | 352.83 |
| Earnings Per Share (Basic) | 1.86 | 6.94 |
The results were reviewed by the Audit Committee and approved by the Board of Directors on August 14, 2026. The statutory auditors confirmed that the Unaudited Financial Results for the quarter ended June 30, 2026, were subjected to a limited review by their firm, Rai Qimat & Associates, resulting in an unmodified conclusion.
Corporate Governance and Shareholder Matters
The Board also approved the draft Annual Report of the Company for the financial year 2025-26 and the draft Cost Audit Report for the same period.Regarding shareholder matters, the board approved the closure of the Register of Members and other Transfer Books from Saturday, September 19, 2026, to Friday, September 25, 2026. This closure is linked to the proposed payment of a Final Dividend at 10% or Re. 1/- per Equity Share, subject to approval by members at the upcoming Annual General Meeting.
Addressing Regulatory Penalties and Compliance
The Board meeting reviewed notices received from BSE Limited and National Stock Exchange of India Limited concerning non-compliance matters under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Specifically, the board noted a fine levied by BSE for non-compliance with Regulation 19(1)/19(2), which related to the constitution of the Nomination and Remuneration Committee by including an Executive Member instead of a Non-Executive Member.
The fine details associated with this instance were:
| Exchange | Regulation Violated | Fine Amount per Instance (Rs.) | Total Fine Payable (Incl. GST @ 18%) |
|---|---|---|---|
| BSE Limited | Regulation 19(1)/19(2) | 5,000 | 1,10,920 |
The company confirmed that the payments for these fines were made to both exchanges on June 02, 2026. The Board further directed concerned officials of the Company to undertake all necessary corrective and compliance measures as per the notices received from the Stock Exchanges.
MEDICAMEQ Stock Price Movement
Medicamen Biotech Limited shares today slipped by 1.25% to close at ₹240.45, shedding ₹3.02 from its previous closing price. The stock traded within a defined range for the day, finding support at a low of ₹232.05 and topping out at ₹244.54.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.